RCKT Stock Analysis: Buy, Sell, or Hold?
RCKT - Rocket Pharmaceuticals, Inc. Common Stock
$3.77
-0.92 (-19.62%)
▼
5d:
-8.94%
30d:
-16.78%
90d:
+6.8%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
RCKT is down 7.2% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 633 OI. Call ratio: 97% View Scanner →
Strength: 8.3/10
Get Alerted When RCKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RCKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RCKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RCKT is currently trading at $3.77, which is considered oversold relative to its 30-day fair value range of $3.97 to $4.95.
Technical Outlook: Technically, RCKT is in a strong uptrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 19.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.20 (+117.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RCKT is in a strong uptrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 19.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.20 (+117.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.97 -
$4.95
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-19.6%)
- BULLISH: Trading 117.6% below Wall St target ($8.20)
- CAUTION: Recommendation downgraded due to -8.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$3.97 -
$4.95
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$5.14
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.11
Wall Street Target
$8.20
(+117.6%)
Share & Embed Analysis
Last updated: March 30, 2026 8:51 AM ET
Data refreshes hourly during market hours. Next update: 9:51 AM
Data refreshes hourly during market hours. Next update: 9:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
John Militello
SELL
1157 shares
2026-02-18
Gaurav Shah
SELL
12279 shares
2026-02-13
John Militello
SELL
3726 shares
2026-02-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
